{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T20:18:36Z","timestamp":1792441116431,"version":"4.5.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,4,1]],"date-time":"2020-04-01T00:00:00Z","timestamp":1585699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Indian Journal of Tuberculosis"],"published-print":{"date-parts":[[2020,4]]},"DOI":"10.1016\/j.ijtb.2020.03.002","type":"journal-article","created":{"date-parts":[[2020,3,24]],"date-time":"2020-03-24T19:44:09Z","timestamp":1585079049000},"page":"222-230","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients"],"prefix":"10.1016","volume":"67","author":[{"given":"Sandip V.","family":"Barvaliya","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mira K.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jigar R.","family":"Panchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rajesh N.","family":"Solanki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijtb.2020.03.002_bib1","series-title":"Global Tuberculosis Report","author":"World Health Organization","year":"2017"},{"key":"10.1016\/j.ijtb.2020.03.002_bib2","unstructured":"\u2018First National Tuberculosis Drug Resistance Survey in India\u2019 Available from: https:\/\/tbcindia.gov.in\/showfile.php?lid=3315 (accessed on 29 July 2019)."},{"issue":"2","key":"10.1016\/j.ijtb.2020.03.002_bib3","doi-asserted-by":"crossref","first-page":"145","DOI":"10.4103\/0976-500X.130062","article-title":"Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis","volume":"5","author":"Jain","year":"2014","journal-title":"J Pharmacol Pharmacother"},{"issue":"8","key":"10.1016\/j.ijtb.2020.03.002_bib4","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1371\/journal.pmed.1001062","article-title":"Commercial serological tests for the diagnosis of active pulmonary and extrapulmonary tuberculosis: an updated systematic review and meta-analysis","volume":"8","author":"Steingart","year":"2011","journal-title":"PLoS Med"},{"issue":"4","key":"10.1016\/j.ijtb.2020.03.002_bib5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.5588\/ijtld.14.0335","article-title":"QTc prolongation and treatment of multidrug-resistant Tuberculosis","volume":"19","author":"Harausz","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"issue":"5","key":"10.1016\/j.ijtb.2020.03.002_bib6","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1177\/2042098612454283","article-title":"Drug-induced QT interval prolongation: mechanisms and clinical management","volume":"3","author":"Nachimuthu","year":"2012","journal-title":"Ther Adv Drug Saf"},{"issue":"8","key":"10.1016\/j.ijtb.2020.03.002_bib7","doi-asserted-by":"crossref","first-page":"979","DOI":"10.5588\/ijtld.14.0944","article-title":"Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis","volume":"19","author":"Ndjeka","year":"2015","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.ijtb.2020.03.002_bib8","doi-asserted-by":"crossref","first-page":"1230","DOI":"10.1016\/S0140-6736(13)62675-6","article-title":"Long-term outcomes of patients with extensively drug-resistant tuberculosis in South Africa: a cohort study","volume":"5","author":"Pietersen","year":"2014","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ijtb.2020.03.002_bib9","first-page":"594","article-title":"Survival and predictors of outcomes in non-HIV- infected patients with extensively drug-resistant tuberculosis","volume":"13","author":"Jeon","year":"2009","journal-title":"Int J Tubercul Lung Dis"},{"key":"10.1016\/j.ijtb.2020.03.002_bib10","doi-asserted-by":"crossref","first-page":"289","DOI":"10.4103\/ijmy.ijmy_59_17","article-title":"Treatment outcome of patients having extensively drug resistant tuberculosis in Gujarat, India","volume":"6","author":"Prajapati","year":"2017","journal-title":"Int J Mycobacteriol"},{"issue":"3","key":"10.1016\/j.ijtb.2020.03.002_bib11","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01799-2016","article-title":"Long term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis","volume":"49","author":"Guglielmetti","year":"2017","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ijtb.2020.03.002_bib12","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1183\/13993003.00724-2015","article-title":"Bedaquiline in the treatment of multidrug-and extensively drug-resistant tuberculosis","volume":"47","author":"Pym","year":"2016","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijtb.2020.03.002_bib13","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jinf.2018.08.003","article-title":"Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery","volume":"78","author":"Borisov","year":"2019","journal-title":"J Infect"},{"issue":"8","key":"10.1016\/j.ijtb.2020.03.002_bib14","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1056\/NEJMoa1313865","article-title":"Multidrug-resistant tuberculosis and culture conversion with bedaquiline","volume":"371","author":"Diacon","year":"2014","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.ijtb.2020.03.002_bib15","doi-asserted-by":"crossref","first-page":"4097","DOI":"10.1128\/AAC.00120-13","article-title":"WHO group 5 drugs and difficult multidrug-resistant tuberculosis: a systematic review with cohort analysis and meta-analysis","volume":"57","author":"Chang","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"issue":"2","key":"10.1016\/j.ijtb.2020.03.002_bib16","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1183\/09031936.00009509","article-title":"A retrospective TBNET assessment of linezolid safety, tolerability and efficacy in MDR-TB","volume":"34","author":"Migliori","year":"2009","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.ijtb.2020.03.002_bib17","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1183\/09031936.00022912","article-title":"Efficacy, safety and tolerability of linezolid containing regimens in treating MDR-TB and XDR-TB: systematic review and meta-analysis","volume":"40","author":"Sotgiu","year":"2012","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ijtb.2020.03.002_bib18","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1093\/cid\/ciu786","article-title":"Compassionate use of bedaquiline for the treatment of multidrug-resistant and extensively drug-resistant tuberculosis: interim analysis of a French cohort","volume":"60","author":"Guglielmetti","year":"2014","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.ijtb.2020.03.002_bib19","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1007\/s40264-015-0267-y","article-title":"Safety and tolerability profile of second-line anti-tuberculosis medications","volume":"38","author":"Ramachandran","year":"2015","journal-title":"Drug Saf"},{"issue":"5","key":"10.1016\/j.ijtb.2020.03.002_bib20","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S1473-3099(18)30100-2","article-title":"Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study","volume":"18","author":"Ferlazzo","year":"2018","journal-title":"Lancet Infect Dis"},{"issue":"3","key":"10.1016\/j.ijtb.2020.03.002_bib21","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1473-3099(09)70041-6","article-title":"Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis","volume":"9","author":"Orenstein","year":"2009","journal-title":"Lancet Infect Dis"},{"issue":"2","key":"10.1016\/j.ijtb.2020.03.002_bib22","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/S0306-4530(97)00080-2","article-title":"The effects of nicotine on the immune system","volume":"23","author":"McAllister-Sistilli","year":"1998","journal-title":"Psychoneuroendocrinology"}],"container-title":["Indian Journal of Tuberculosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001957072030041X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S001957072030041X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,17]],"date-time":"2025-09-17T03:58:42Z","timestamp":1758081522000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S001957072030041X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,4]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,4]]}},"alternative-id":["S001957072030041X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijtb.2020.03.002","relation":{},"ISSN":["0019-5707"],"issn-type":[{"value":"0019-5707","type":"print"}],"subject":[],"published":{"date-parts":[[2020,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Early treatment outcome of bedaquiline plus optimised background regimen in drug resistant tuberculosis patients","name":"articletitle","label":"Article Title"},{"value":"Indian Journal of Tuberculosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijtb.2020.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Tuberculosis Association of India. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}